Repair or replacement for severe ischemic mitral regurgitation
A meta-analysis
Xinxin Wang, MD, Bo Zhang, MD, Jian Zhang, MD, Yongquan Ying, MD, Chengchu Zhu, MD, Baofu Chen, MD

Abstract
Background: The best surgical option for severe ischemic mitral regurgitation (IMR) is still controversial. The aim of this study was to perform a meta-analysis to compare the clinical outcomes of mitral valve repair (MVP) with replacement (MVR).

Methods: A literature search was conducted in PubMed, Embase, and Medline using the terms “ischemic mitral regurgitation” and “repair or annuloplasty or reconstruction” and “replacement” in the title/abstract field. The primary outcomes of interest were perioperative mortality and long-term survival. Secondary outcomes were mitral regurgitation (MR) recurrence and reoperation.

Results: Of 276 studies, 13 studies met the inclusion and exclusion criteria. A total of 1993 patients were included in these studies, consisting of 1259 (63%) repair cases, and 734 (37%) replacement cases. Perioperative mortality was lower with MVP compared with MVR [OR 0.61; (95% CI, 0.43–0.87; P < .05)]. There was no difference with respect to long-term survival [HR 0.75; (95% CI, 0.52–1.09; P = .14)] and reoperation [OR 0.77; (95% CI, 0.38–1.57; P = .47)]. MVP is associated with a higher recurrence of MR [OR = 4.09; (95% CI, 1.82–9.19; P < .001)].

Conclusion: MVP is associated with a lower perioperative mortality but a higher recurrence of MR compared with MVR for severe IMR. No differences were found with respect to long-term survival and reoperation.

Abbreviations: CABG = coronary artery bypass grafting, CI = confidence interval, IMR = ischemic mitral regurgitation, LVEF = left ventricle ejection fraction, MR = mitral regurgitation, MVP = mitral valve repair, MVR = mitral valve replacement, NOS = Newcastle–Ottawa scale, NYHA = New York Heart Association, OR = odds ratio, RR = relative risk, SVA = subvalvular apparatus.

Keywords: coronary artery bypass grafting, meta-analysis, mitral valve repair, mitral valve replacement, severe ischemic mitral regurgitation.

1. Introduction
Chronic ischemic mitral regurgitation (IMR) is a common and important complication after myocardial infarction. The presence of IMR is estimated to be 20% to 30% after acute myocardial infarction.[1] The pathophysiological mechanism of IMR includes adverse remodeling of left ventricle, mitral annular dilatation, and leaflet tethering.[2]

For less than severe IMR coronary artery bypass grafting (CABG) alone is recommended by guidelines as additional MV surgery would not add benefit to the short- and long-term outcome for patients.[3] However, the optimal surgery treatment for severe IMR is still debatable. There has been lots of studies comparing these 2 surgery techniques in the past few decades and the recommendation was divergent. Previous meta-analyses drew a conclusion that mitral valve repair (MVP) is associated with better short-term results but with a high recurrence of mitral regurgitation compared with replacement for IMR.[4–8] Wang and colleagues[9] failed to find a better operative mortality outcome with repair for patients undergoing concomitant CABG. On the reoperation rate and long-term survival, meta-analyses drew different conclusions.[4–8] In addition, these meta-analyses had included patients with less than severe IMR which could be not appropriate to apply the conclusion for patients with severe IMR. Although Wang and colleagues[10] had conducted a subgroup meta-analysis on severe IMR, they only included 3 studies which was not enough to draw a convincing result. So there is still need to perform a meta-analysis of the available evidence of the best option for severe IMR.

2. Materials and methods
2.1. Search strategy
We conducted a literature search in electronic databases including PubMed, Embase, and Medline for all relevant literature from the date of database inception to June 2017. The following search terms were searched in the title/abstract field: “ischemic mitral regurgitation” and “repair or annul-
plasty or reconstruction” and “replacement.” Only English articles were included. The reference lists of relevant review articles were checked to identify extra relevant articles.

2.2. Inclusion and exclusion criteria

Articles are included if there is a direct comparison of repair versus replacement for severe IMR. Articles were excluded if they met the following criteria: no direct comparison between repair and replacement, nonischemic etiology of MR or ischemic etiology only in a subset of the patients, part of patients with preoperative severity of MR lower than 3+ or 4+, (4) nonischemic dilated cardiomyopathy, and (5) concomitant ventricle restoration surgery.

2.3. Data extraction

Data were extracted independently by 2 authors (XW and BZ). If there was a disagreement, consensus was achieved by discussion. The following data were extracted from each included articles: first author, publication year, study design, patients’ age and gender, comorbidities, New York Heart Association (NYHA) cardiac function, operation techniques, concomitant procedure, adjusted or crude odds ratio (OR), or hazard ratio (RR) with 95% confidence intervals (CIs).

2.4. Quality assessment

The Newcastle–Ottawa scale (NOS) was used to access the quality of included studies, with the highest score of 9. The high-quality study was defined as a study with a score≥6. The assessment was performed independently by 2 authors (JZ and YY). If necessary, a third author (BC) was consulted to settle disagreements.

2.5. Statistical methods

Review Manager version 5.3 (The Cochrane Collaboration, Copenhagen, Denmark) and Stata (version 12.0; StataCorp, College Station, TX) were used to perform all statistical analyses. Heterogeneity was calculated by the Q-test and I² statistics.

Figure 1. Flowchart of studies selection.
Studies with an $I^2$ statistics of $>50\%$ were considered of a high degree of heterogeneity. Heterogeneity was assessed by subgroup analysis. A summary of OR and its corresponding 95% CI were computed for the dichotomous outcomes using either random-effects models in the presence of large heterogeneity ($I^2 > 50\%$), or fixed-effects models. HR and the corresponding 95% CI were used for long-term mortality either directed provided by articles or indirectly calculated using the method of Tierney and colleagues\{11\} in each study. Publication bias was assessed qualitatively using funnel plots and quantitatively using Egger’s linear regression method and Begg’s rank correlation test. A $P$ value $< .05$ was considered statistically significant.

2.6. Ethics
The article was a meta-analysis based on the results of studies published and the ethical approval was not necessary.

3. Results
The literature search identified a total of 276 studies for review. Based on the titles and abstracts, 27 articles were selected and reviewed for full text. Of these, 2 articles were excluded because the data were from the same study.\{12,13\} One article was eliminated because they included patients with concomitant restoration surgery.\{14\} Around 3 articles were excluded because they did not provide direct comparison between repair and replacement.\{15–17\} A total of 8 articles were eliminated because they either did not provide the MR grade of the patients or included patients of MR grade $<3$.\{18–25\} Finally, 13 articles met the inclusion and exclusion criteria (Fig. 1).\{26–38\} Of the included articles, there were 12 retrospective observational studies and 1 randomized controlled study. These studies included a total of 1993 patients, 1259 of whom underwent repair and 734 of whom underwent replacement. Patient characteristics and operation details are summarized in Table 1. All the nonrandomized studies were assessed using the Newcastle–Ottawa scale for quality assessment and were of high quality (≥6 scores) (Table 2). Out of the 13 studies, age was reported in 10, gender in 11, hypertension in 6, diabetes in 9, preoperative mean left ventricle ejection fraction (LVEF) in 8, NYHA class in 9, subvalvular apparatus (SVA)-sparing techniques in 10, and concomitant CABG in 13. There were no significant differences in age except for 3 studies in which the replacement patients were 3 to 5 years older than repair patients. Only 1 study had significant more diabetes and 2 studies had significant better LVEF in MVP group. In addition, the 2 groups were similar with respect to hypertension and NYHA. Around 12 studies reported the use of annuloplasty ring and 9 studies reported the detail of SVA-sparing techniques.

3.1. Perioperative mortality
All the included studies reported perioperative mortality. The ORs ranged from 0.16 to 2.24 in studies (Fig. 2). The summary OR was 0.61 (95% CI, 0.43–0.87; $P < .05$) indicating there was a significantly lower perioperative mortality trend towards repair. $I^2 = 0$ indicated there was no potential heterogeneity across the studies. Funnel plot analysis showed symmetry (Fig. 3). No publication bias was found through Egger’s linear regression method ($P = .92$) and Begg’s rank correlation test ($P = .54$).

3.2. Long-term survival
A total of 11 studies reported long-term survival (Fig. 4). The overall HR was 0.75 (95% CI, 0.52–1.09; $P = .14$), suggesting
long-term survival was not significantly improved following repair. The heterogeneity was high ($I^2 = 58\%$). Subgroup analyses were conducted considering the high heterogeneity. Around 7 of 11 studies performing mitral valve surgery with concomitant CABG were pooled (Fig. 5). The subgroup HR was 0.81 (95\% CI, 0.60–1.10; $P = .19$) with a moderate heterogeneity ($I^2 = 31\%$), which still indicated no significant difference between repair and replacement on long-term survival. 5 of 11 studies using SVA-sparing techniques in all MVR patients were analysed separately (Fig. 6), long-term survival still showed no significant difference between repair and replacement (HR = 0.58, 95\% CI, 0.31–1.08; $P = .09$). As was the same when restricting studies to only posterior SVA preservation (HR = 0.92, 95\% CI, 0.36–2.30; $P = .85$). However, there was a high heterogeneity among these studies, which adds a caution to these results.

3.3. Reoperation
About 7 studies involving a total of 805 patients reported reoperation during follow-up due to mitral regurgitation recurrence, thrombosis, paravalvular leak, endocarditis, et al (Fig. 7). The overall OR was 0.77, indicating the trend toward the preference of repair. However, there was no significant difference between repair and replacement (95\% CI, 0.38–1.57; $P = .47$). There was no potential heterogeneity across the studies ($I^2 = 0$).

3.4. Mitral regurgitation recurrence
Around 5 studies involving a total of 449 patients provided data regarding recurrence of MR during the follow-up (Fig. 8). The repair group was associated with a significant increased
recurrence rate of MR (OR = 4.09, 95% CI 1.82–9.19; \( P < .001 \)) with a low heterogeneity across the studies (\( I^2 = 22\% \)).

4. Discussion

Although several meta-analyses had reported their results on MVR versus MVP, these analyses had included studies involving patients with less severe IMR (MR \( \leq 2+ \)).[4–9] Wang and colleagues[10] reported a subgroup analysis about repair versus replacement for severe IMR, only 3 included studies were not enough to compare these 2 techniques. Our study is the first meta-analysis which included 13 articles to compare repair with replacement for severe IMR.

It has been well established mitral valve repair is superior to replacement for degenerative mitral valve disease. Mitral valve repair has an advantage of lower operative mortality, higher long-term survival, fewer valve-related complications and better preservation of ventricular function.[39–46] However, the benefit of MVP over MVR for severe IMR is not clear.

In our meta-analysis of 13 studies, MVP was found to be with significant lower perioperative mortality. There was no significant difference regarding long-term mortality and reoperation. Mitral repair was associated with a significant higher incidence of mitral regurgitation.

Our meta-analysis confirms the advantage of repair compared with replacement in perioperative mortality for severe IMR. Our result should be considered as a good supplement to the conclusion that repair was superior to replacement for IMR which was reported by previous meta-analyses. The superiority of repair over replacement for degenerative valve disease has been

---

**Figure 3.** Funnel plot analysis.

**Figure 4.** Mitral valve repair versus mitral valve replacement on long-term survival.
Figure 5. Mitral valve repair versus mitral valve replacement with concomitant coronary artery bypass graft on long-term survival.

Figure 6. Mitral valve repair versus mitral valve replacement with different subvalvular apparatus preservation techniques on long-term survival.

Figure 7. Mitral valve repair versus mitral valve replacement on reoperation during follow-up.
explained partly with the preservation of the subvalvular apparatus and the subsequent protection on left ventricular function. Since Lillehei et al.[47] introduced the concept of preservation of posterior subvalvular apparatus for mitral valve repair in 1964, the contribution of the subvalvular apparatus to protection of postoperative ventricular function has been confirmed by large amount of studies.[48–50] Recently, preservation of both the anterior and posterior leaflets confirmed a greater benefit over the preservation of posterior leaflet alone in left ventricle remodeling and reducing systolic afterload, and improving ventricle performance.[51,52] In our subgroup analysis according to the preservation of subvalvular apparatus, we still confirmed the preference of MVP over MVR in the long-term survival although it was not statistically significant. This adds to the validity of our results on long-term survival after repair compared with replacement in patients with severe IMR.

Recurrence of MR has been found to be a common complication for MVP in the treatment of IMR and degenerative MR.[53,54] Our study contributes further evidence to the high recurrence of MR after MVP. However, we didn’t find a significant difference in reoperation rate between these 2 treatments. It could be explained for several possible reasons. Firstly, the reasons for repeat operation were not restricted to the recurrence of MR. Other reasons for repeat operation were endocarditis, thrombosis, paravalvular leak and structural deterioration of bioprosthetic valve, most of which were related to MVR.[23,25,31,33] Secondly, although there was an indication for repeat operation for the recurrence of MR, risks may be substantial considering the underlying myocardial disease and surgeons tend to take conservative measures to treat these high-risk patients.[55] Thirdly, the recurrence of MR was defined to be MR of 2+ or greater. Some of the patients with recurrence of MR may not reach the indication for repeat operation.

4.1. Limitations

Our study has several limitations. Firstly, this meta-analysis include observational, retrospective studies with the inherent biases of study design. The publications except one random controlled study were relatively small nonrandomized studies. Secondly, the follow-up data of changes on NYHA class, LVEF and left ventricle remodeling were not provided in most of the studies which prevented the further analysis of these 2 surgical techniques in these aspects. Thirdly, the confounding factors such as age, EF, SVA preservation techniques and concomitant CABG were not adjusted in the studies. Well-designed multi-center RCTs are still needed to draw a convincing conclusion.

5. Conclusion

We draw a conclusion that MVP is associated with a significant lower perioperative mortality compared with MVR for severe IMR. There is no significant difference with respect to long-term survival and reoperation between these 2 surgical techniques. However, MVP is associated with a higher recurrence of MR.

Author contributions

Funding acquisition: Yongquan Ying.
Methodology: Jian Zhang.
Project administration: Chengchu Zhu.
Resources: Bo Zhang.
Writing – original draft: Xinxin Wang.
Writing – review & editing: Baofu Chen.

References

[1] Bursi F, Enriquez-Sarano M, Nkomo VT, et al. Heart failure and death after myocardial infarction in the community. The emerging role mitral regurgitation. Circulation 2003;111:293–301.
[2] Pierard LA, Carabello BA. Ischaemic mitral regurgitation: pathophysiology, outcomes and the conundrum of treatment. Eur Heart J 2010;31:2996–3005.
[3] Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:e139–e284.
[4] Salmisi MY, Acharaya M, Humayun N, et al. Is valve repair preferable to valve replacement in ischaemic mitral regurgitation? A systematic review and meta-analysis. Eur J Cardiothorac Surg 2016;50:17–28.
[5] Dayan V, Soca G, Cara L, et al. Similar survival after mitral valve replacement or repair for ischemic mitral regurgitation: a meta-analysis. Ann Thorac Surg 2014;97:758–63.
[6] Vyrk SA, Srinivandrarajah A, Dunn D, et al. A meta-analysis of mitral valve repair versus replacement for ischemic mitral regurgitation. Ann Cardiothorac Surg 2015;4:400–10.
[7] Yun-Dan D, Wen-Jing D, Xi-Jun X. Comparison of outcomes following mitral valve repair versus replacement for chronic ischemic mitral regurgitation: a meta-analysis. Thorac Cardiovasc Surg 2016;64:432–41.
[8] Vassileva CM, Boley T, Markwell S, et al. Meta-analysis of short-term and long-term survival following repair versus replacement for ischemic mitral regurgitation. Eur J Cardiothorac Surg 2011;39:295–303.
[9] Wang Y, Shi X, Wen M, et al. Repair or replace ischemic mitral regurgitation during coronary artery bypass grafting? A meta-analysis. J Cardiothorac Surg 2016;11:141.
[10] Wang J, Gu C, Gao M, et al. Mitral valve replacement therapy causes higher 30-day postoperative mortality than mitral valvuloplasty in patients with severe ischemic mitral regurgitation: a meta-analysis of 12 studies. Int J Cardiol 2015;183:304–7.

[11] Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.

[12] Chan V, Levac-Martinho O, Sohmer B, et al. When should the mitral valve be repaired or replaced in patients with ischemic mitral regurgitation? Ann Thorac Surg 2017;103:742–7.

[13] Cohn LH, Kowaler W, Bhatia S, et al. Comparative morbidity of mitral valve repair versus replacement for mitral regurgitation with and without coronary artery disease. Ann Thorac Surg 1998;45:284–90.

[14] Isomura T, Suna H, Yamaguchi A, et al. Left ventricular restoration for ischemic cardiomyopathy—comparison of presence and absence of mitral valve procedure. Eur J Cardiothorac Surg 2003;23:514–9.

[15] Castleberry AW, Williams JB, Daneshmand MA, et al. Surgical revascularization is associated with maximal survival in patients with ischemic mitral regurgitation: a 20-year experience. Circulation 2014;129:2547–56.

[16] Fino C, Iacovoni A, Ferrero P, et al. Restrictive mitral valve annuloplasty versus mitral valve replacement for functional ischemic mitral regurgitation: an exercise echocardiographic study. J Thorac Cardiovasc Surg 2014;148:447.e2–53.e2.

[17] Fino C, Iacovoni A, Ferrero P, et al. Determinants of functional capacity after mitral valve annuloplasty or replacement for ischemic mitral regurgitation. J Thorac Cardiovasc Surg 2015;149:1595–603.

[18] Mantovani V, Marischi G, Leva C, et al. Long-term results of the surgical treatment of chronic ischemic mitral regurgitation: comparison of repair and prosthetic replacement. J Heart Valve Dis 2004;13:421–8. discussion 28–9.

[19] Reece TB, Tribble CG, Ellman PL, et al. Mitral repair is superior to replacement when associated with coronary artery disease. Ann Surg 2004;239:671–5. discussion 75–7.

[20] Gillinov AM, Wierup PN, Blackstone EH, et al. Is repair preferable to replacement for ischemic mitral regurgitation? J Thorac Cardiovasc Surg 2001;122:1125–41.

[21] Califore AM, Di Mauro M, Gallina S, et al. Mitral valve surgery for chronic ischemic mitral regurgitation. Ann Thorac Surg 2004;77:1989–97.

[22] Milano CA, Daneshmand MA, Rankin JS, et al. Survival prognosis and surgical management of ischemic mitral regurgitation. Ann Thorac Surg 2008;86:735–44.

[23] Al-Radi OO, Austin PC, Tu JV, et al. Mitral repair versus replacement for ischemic mitral regurgitation. Ann Thorac Surg 2005;79:1260–6. discussion 60-7.

[24] Magne J, Girerd N, Senechal M, et al. Mitral valve repair versus replacement for ischemic mitral regurgitation: comparison of short-term and long-term survival. Circulation 2009;120[11 suppl]:S104–11.

[25] Lorusso R, Gelsomino S, Vizzardi E, et al. Mitral valve repair or replacement for ischemic mitral regurgitation? The Italian Study on the Treatment of Ischemic Mitral Regurgitation [ISTIMIR]. J Thorac Cardiovasc Surg 2013;145:128–39.

[26] Cohn LH, Ruzzo RJ, Adams DH, et al. The effect of pathophysiology on the surgical treatment of ischemic mitral regurgitation: operative and late risks of repair versus replacement. Eur J Cardiothorac Surg 1995;9:568–74.

[27] Grossi EA, Goldberg JD, LaPietra A, et al. Ischemic mitral valve reconstruction and replacement: comparison of long-term survival and complications. J Thorac Cardiovasc Surg 2001;122:1107–24.

[28] Silberman S, Oren A, Klutstein MW, et al. Does mitral valve intervention have an impact on late survival in ischemic cardiomyopathy? is Med Assoc J 2006;81:7–20.

[29] Bonachhi M, Prieto E, Maiani M, et al. Mitral valve surgery simultaneous to coronary revascularization in patients with end-stage ischemic cardiomyopathy. Heart Vessels 2006;21:20–7.

[30] Mivocov S, Milacic P, Orasovic P, et al. Comparison of valve annuloplasty and replacement for ischemic mitral valve incompetence. Heart Surg Forum 2008;11:E340–5.

[31] Qiu Z, Chen X, Xu M, et al. Is mitral valve repair superior to replacement for chronic ischemic mitral regurgitation with left ventricular dysfunction? J Cardiothorac Surg 2010;5:107.

[32] Maltas S, Schaff HV, Daly RC, et al. Mitral regurgitation surgery in patients with ischemic cardiomyopathy and ischemic mitral regurgitation: factors that influence survival. J Thorac Cardiovasc Surg 2011;142:995–1001.

[33] Chan V, Ruel M, Mesana TG. Mitral valve replacement is a viable alternative to mitral valve repair for ischemic mitral regurgitation: a case-matched study. Ann Thorac Surg 2011;92:1338–65. discussion 65–6.

[34] De Bonis M, Ferrara D, Taramasso M, et al. Mitral replacement or repair for functional mitral regurgitation in dilated and ischemic cardiomyopathy: is it really the same? Ann Thorac Surg 2012;94:44–51.

[35] Roshanali F, Vedadian A, Shoar S, et al. When to repair ischemic mitral valve regurgitation? An algorithmic approach. Eur Surg 2013;45:98–105.

[36] Ljubacev A, Medved I, Ostric M, et al. Mitral regurgitation and coronary artery bypass surgery; comparison of mitral valve repair and replacement. Acta Chir Belg 2013;1:187–91.

[37] Loo A. Mitral valve repair versus replacement in patients with ischaemic mitral regurgitation and depressed ejection fraction: risk factors for early and mid-term mortality? Interact Cardiovasc Thorac Surg 2014;19:64–9.

[38] Acker MA, Parades MK, Perrault LP, et al. Mitral valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med 2014;370:23.

[39] Grossi EA, Galloway AC, Miller JS, et al. Valve repair versus replacement for mitral insufficiency: when is a mechanical valve still indicated? J Thorac Cardiovasc Surg 1998;115:194–8.

[40] Kawachi Y, Oe M, Asou T, et al. Comparative study between valve repair and replacement for mitral pure regurgitation—early and late postoperative results. Jap Circ J 1991;55:443–52.

[41] Ren JF, Akut S, Lighty GW, Jr, et al. Mitral valve repair is superior to valve replacement for the early preservation of cardiac function: relation of ventricular geometry to function. Am Heart J 1996;131:974–81.

[42] Okita Y, Miki S, Ueda Y, et al. Comparative evaluation of left ventricular performance after mitral valve repair or valve replacement with or without chordal preservation. J Heart Valve Dis 1993;2:159–66.

[43] Sand ME, Nafel DC, Blackstone EH, et al. A comparison of repair and replacement for mitral valve incompetence. J Thorac Cardiovasc Surg 1987;94:208–19.

[44] Perser P, Deloache A, Chauvadu S, et al. Comparative evaluation of mitral valve repair and replacement with Starr, Björk, and porcine valve prostheses. Circulation 1984;70:187–92.

[45] Tischler MD, Cooper KA, Rowen M, et al. Mitral valve replacement versus mitral valve repair. A Doppler and quantitative stress echocardiographic study. Circulation 1994;89:132–7.

[46] Galloway AC, Colvin SB, Baumann FG, et al. A comparison of mitral valve reconstruction with mitral valve replacement: intermediate-term results. Ann Thorac Surg 1989;47:655–62.

[47] Lillehei CW, Levy MJ, Bonnabaeu RC, Jr, Mitral valve replacement with preservation of papillary muscles and chordae tendineae. J Thorac Cardiovasc Surg 1964;13:117–8.

[48] Reardon MJ, David TE. Mitral valve replacement with preservation of the sub-valvular apparatus during mitral valve replacement affect long-term survival and quality of life? A Microsimulation Study. J Cardiothorac Surg 2008;3:1–9.

[49] Tajedemir O, Katicioğlu F, Catar Z, et al. Clinical results of mitral valve replacement with and without preservation of the posterior mitral valve leaflet and subvalvular apparatus. J Cardiovasc Surg 1991;32:109.

[50] Yun KL, Sintrck CF, Miller DC, et al. Randomized trial comparing partial versus complete chordal-sparing mitral valve replacement: effects on left ventricular volume and function. J Thorac Cardiovasc Surg 2002;123:707–14.

[51] Yun KL, Sintrck CF, Miller DC, et al. Randomized trial of partial versus complete chordal preservation methods of mitral valve replacement: a preliminary report. Circulation 1999;100[19 suppl]:90–4.

[52] Bonis MD, Lapenna E, Verzini A, et al. Recurrence of mitral regurgitation parallels the absence of left ventricular reverse remodeling after mitral repair in advanced dilated cardiomyopathy. Ann Thorac Surg 2008;85:922–9.

[53] Ciarka A, Braun J, Delgado V, et al. Predictors of mitral regurgitation recurrence in patients with heart failure undergoing mitral valve annuloplasty. Am J Cardiol 2010;106:395.

[54] McGee EC, Gillinov AM, Blackstone EH, et al. Recurrent mitral regurgitation after annuloplasty for functional ischemic mitral regurgitation. J Thorac Cardiovasc Surg 2004;128:916–24.